JP2022523919A - 神経変性疾患を治療するための物質および方法 - Google Patents

神経変性疾患を治療するための物質および方法 Download PDF

Info

Publication number
JP2022523919A
JP2022523919A JP2021545944A JP2021545944A JP2022523919A JP 2022523919 A JP2022523919 A JP 2022523919A JP 2021545944 A JP2021545944 A JP 2021545944A JP 2021545944 A JP2021545944 A JP 2021545944A JP 2022523919 A JP2022523919 A JP 2022523919A
Authority
JP
Japan
Prior art keywords
fenofibrate
kaempferol
subject
disease
pgc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021545944A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523919A5 (https=
Inventor
ハワード・ジェイ・フェデロフ
スダカール・ラジャ・スブラマニアム
マッシモ・エス・フィアンダカ
マーク・イー・マプストン
シアオミン・スー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
University of California San Diego UCSD
Original Assignee
Georgetown University
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University, University of California San Diego UCSD filed Critical Georgetown University
Publication of JP2022523919A publication Critical patent/JP2022523919A/ja
Publication of JP2022523919A5 publication Critical patent/JP2022523919A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021545944A 2019-02-05 2020-02-05 神経変性疾患を治療するための物質および方法 Pending JP2022523919A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962801271P 2019-02-05 2019-02-05
US62/801,271 2019-02-05
PCT/US2020/016820 WO2020163493A2 (en) 2019-02-05 2020-02-05 Materials and methods for treating a neurodegenerative disease

Publications (2)

Publication Number Publication Date
JP2022523919A true JP2022523919A (ja) 2022-04-27
JP2022523919A5 JP2022523919A5 (https=) 2023-02-14

Family

ID=71947875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021545944A Pending JP2022523919A (ja) 2019-02-05 2020-02-05 神経変性疾患を治療するための物質および方法

Country Status (9)

Country Link
US (1) US20220401404A1 (https=)
EP (1) EP3930711A4 (https=)
JP (1) JP2022523919A (https=)
CN (1) CN114007607A (https=)
AU (1) AU2020219140A1 (https=)
BR (1) BR112021015466A2 (https=)
CA (1) CA3129050A1 (https=)
MX (1) MX2021009413A (https=)
WO (1) WO2020163493A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021022270A2 (pt) * 2019-05-06 2022-01-11 Univ California Materiais e métodos para tratar degeneração macular relacionada à idade
CN115429788B (zh) * 2022-10-24 2023-11-21 上海中医药大学附属岳阳中西医结合医院 一种治疗脱髓鞘疾病的药物及应用
CN119454686A (zh) * 2024-08-06 2025-02-18 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） 山柰酚或含有山柰酚的组合物在制备治疗和/或缓解多发性硬化症药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
JP2016531162A (ja) * 2013-09-18 2016-10-06 ジョージタウン・ユニバーシティＧｅｏｒｇｅｔｏｗｎ Ｕｎｉｖｅｒｓｉｔｙ フェノフィブラート及びその類似体を用いた神経変性疾患の治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
WO2009147009A2 (en) * 2008-06-06 2009-12-10 Nicox S.A. Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug
US20130252924A1 (en) * 2010-11-11 2013-09-26 Akron Molecules Gmbh Compounds and Methods for Treating Pain
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof
CN109069450A (zh) * 2016-02-05 2018-12-21 法奈克斯公司 神经障碍的新的组合疗法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
JP2016531162A (ja) * 2013-09-18 2016-10-06 ジョージタウン・ユニバーシティＧｅｏｒｇｅｔｏｗｎ Ｕｎｉｖｅｒｓｉｔｙ フェノフィブラート及びその類似体を用いた神経変性疾患の治療

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates)", CLIN PHARMACOKINET, vol. 34(2), JPN6024003129, 1998, pages 155 - 162, ISSN: 0005398833 *
"Effects of Kaempferol, an Antioxidant, on the Bioavailability and Pharmacokinetics of Nimodipine in", JOURNAL OF PHARMACEUTICAL INVESTIGATION, vol. 41, no. 5, JPN6024003128, 2011, pages 301 - 307, ISSN: 0005398832 *
"Fenofibrate Reduces Mortality and Precludes Neurological Deficits in Survivors in Murine Model of Ja", PLOS ONE, vol. Vol.7, Issue 4, JPN6024003130, 2012, pages 1 - 12, ISSN: 0005398834 *
"Kaempferol acts through mitogen-activated protein kinases and protein kinase B/AKT to elicit protect", BRITISH JOURNAL OF PHARMACOLOGY, vol. 164, JPN6024003131, 2011, pages 1008 - 1025, ISSN: 0005398829 *
"Neuroprotective Effect of Kaempferol against a 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyridine-Induced", BIOL. PHARM. BULL., vol. 34(8), JPN6024003126, 2011, pages 1291 - 1296, ISSN: 0005398830 *
PING LI: "Esterase inhibition by grapefruit juice and its components leads to newly identified drug interactio", GRADUATE THESES, DISSERTATIONS, AND PROBLEM REPORTS, vol. 2446, JPN6024003127, 2006, ISSN: 0005398831 *

Also Published As

Publication number Publication date
WO2020163493A2 (en) 2020-08-13
WO2020163493A9 (en) 2020-11-19
US20220401404A1 (en) 2022-12-22
EP3930711A4 (en) 2023-01-11
BR112021015466A2 (pt) 2021-10-19
CN114007607A (zh) 2022-02-01
EP3930711A2 (en) 2022-01-05
MX2021009413A (es) 2022-01-18
CA3129050A1 (en) 2020-08-13
WO2020163493A3 (en) 2020-10-22
AU2020219140A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
Xie et al. Inhibition of ferroptosis attenuates tissue damage and improves long‐term outcomes after traumatic brain injury in mice
Sanadgol et al. Metformin accelerates myelin recovery and ameliorates behavioral deficits in the animal model of multiple sclerosis via adjustment of AMPK/Nrf2/mTOR signaling and maintenance of endogenous oligodendrogenesis during brain self-repairing period
Chung et al. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation
Zhu et al. Neuroprotective effects of Astilbin on MPTP-induced Parkinson's disease mice: Glial reaction, α-synuclein expression and oxidative stress
AU2023282263A1 (en) Isotopically modified components and therapeutic uses thereof
US11826345B2 (en) Dosing regimens of PKC activators
JP6483711B2 (ja) フェノフィブラート及びその類似体を用いた神経変性疾患の治療
JP2001517617A (ja) 神経変性疾患の治療を目的としてａｐｏｅレベルを増加させる方法
JP2022523919A (ja) 神経変性疾患を治療するための物質および方法
Jiang et al. Icariin ameliorates amyloid pathologies by maintaining homeostasis of autophagic systems in Aβ1–42-injected rats
WO2016044314A1 (en) Methods and compositions for treating psychotic disorders
US20240390324A1 (en) Methods of treating and preventing neurodegenerative diseases with hgf activating compounds
JP7850416B2 (ja) 細胞外小胞に含まれるｅｎａｍｐｔの産生および使用
Tanaka et al. Ceramide kinase knockout ameliorates multiple sclerosis-like behaviors and demyelination in cuprizone-treated mice
US20240082184A1 (en) Improved treatment for globoid cell leukodsytrophy or krabbe disease
JP2024523589A (ja) アンジオテンシン及びその類似体の投与によるシナプス形成の誘導方法
US8552058B2 (en) Application of L-n-butylphthalide in preventing and treating dementia
Tran et al. Neuroinflammation Involving Endothelin-1 and Platelet-Activating Factor Receptors Contributes To Self-Injurious Behaviors Induced by Bay k-8644 in Adolescent Mice
US20260060947A1 (en) Electrophilic nitroalkene benzoic acid derivates as therapeutic drugs in amyotrophic lateral sclerosis (als) and other neurodegenerative conditions
Kumar et al. Pharmacological inhibition of IRAK1/4 ameliorates high-fat diet-induced vascular dysfunction and cognitive impairment
KR20250047115A (ko) c-Fos 억제제의 우울/불안 장애를 동반한 파킨슨병 치료 용도
EP4661859A1 (en) Oral phenylbutyrate for treatment of human 4-repeat tauopathies
Gambini et al. Resveratrol in Experimental Models and Humans

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240730

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241223